Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-02-24FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.
-
CLINICAL_TRIALS withdrawal · 2021-02-24Clinical Trial Update: Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis [Phase 3]
Phase 3 trial comparing two etanercept regimens for rheumatoid arthritis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis [Phase 4]
Phase 4 trial assessing subcutaneous ACTEMRA (tocilizumab) on inflamed atherosclerotic plaques in patients with rheumatoid arthritis was ter…
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel [Phase 3]
Phase 3 trial update comparing etanercept and Enbrel for rheumatoid arthritis, focusing on efficacy, safety, and immunogenicity.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA [Phase 3]
Phase 3 trial update comparing CinnoRA to Humira for active rheumatoid arthritis completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: TOward the Lowest Effective DOse of Abatacept or Tocilizumab [Phase 4]
Phase 4 trial updating on achieving the lowest effective dose of abatacept or tocilizumab for rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis [Phase 4]
Phase 4 trial update on optimizing withdrawal strategy of infliximab for rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate [Phase 3]
Phase 3 trial update for filgotinib in combination with methotrexate in adults with moderately to severely active rheumatoid arthritis who h…
-
FDA approval · 2021-01-15FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for AZULFIDINE EN-TABS (sulfasalazine) from Pfizer, resulting in updated labeling and/or approved in…
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy [Phase 3]
Phase 3 trial update on filgotinib alone and with methotrexate in adults with moderately to severely active rheumatoid arthritis who are MTX…
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment [Phase 3]
Phase 3 trial assessing filgotinib versus placebo in adults with active rheumatoid arthritis after inadequate response to biologic DMARDs; r…
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate [Phase 2]
Phase 2 clinical trial of ACTHAR for acute treatment in rheumatoid arthritis patients with inadequate response to methotrexate was terminate…
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: Effect of Baricitinib Treatment on Peripheral Bone in RA [Phase 3]
Phase 3 trial investigating the effect of baricitinib on peripheral bone in rheumatoid arthritis patients.
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function [Phase 1]
Phase 1 pharmacokinetics study of filgotinib in participants with impaired hepatic function completed.
-
CLINICAL_TRIALS trial_result · 2021-01-08Clinical Trial Update: A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX [Phase 3]
Phase 3 study evaluating SM03 in active rheumatoid arthritis patients on MTX.
-
CLINICAL_TRIALS trial_result · 2021-01-08Clinical Trial Update: Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain [NA]
A completed Brigham and Women's Hospital trial evaluated the effects of vitamin D and fish oil on autoimmune inflammation and knee pain; res…
-
FDA approval · 2021-01-07FDA Approved: AZATHIOPRINE SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for azathioprine sodium from Hikma Pharmaceuticals USA Inc., updating the generic product's approval…
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes [Phase 1]
Phase 1 pharmacokinetic study evaluating abatacept converted from drug substance by two processes; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis [Phase 3]
Phase 3 trial comparing CF101 to methotrexate for active rheumatoid arthritis was terminated.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission [Phase 3]
Phase 3 trial comparing etanercept monotherapy to methotrexate monotherapy for maintenance of remission in rheumatoid arthritis.
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
FDA approval · 2020-12-16FDA Approved: ETODOLAC — Original Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved the original ANDA for etodolac from Unichem Pharmaceuticals (USA), Inc., a generic NSAID. It is indicated for relief of sig…
-
FDA approval · 2020-12-12FDA Approved: NAPROXEN SODIUM — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Naproxen Sodium from Bionpharma Inc., resulting in changes to the product labeling. This act…
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy [Phase 3]
Phase 3 trial evaluating ocrelizumab versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate was terminated…
-
FDA approval · 2020-12-03FDA Approved: CELECOXIB — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original ANDA for Celecoxib from ScieGen Pharmaceuticals, a generic version of the COX-2 inhibitor used for pain relief. It…